Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Enterprise Value (2016 - 2026)

Insight Molecular Diagnostics' Enterprise Value history spans 7 years, with the latest figure at -$12.3 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 42.57% to -$12.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.3 million, a 42.57% decrease, with the full-year FY2025 number at -$12.3 million, down 42.57% from a year prior.
  • Enterprise Value hit -$12.3 million in Q4 2025 for Insight Molecular Diagnostics, up from -$19.4 million in the prior quarter.
  • Over the last five years, Enterprise Value for IMDX hit a ceiling of -$866000.0 in Q4 2022 and a floor of -$59.8 million in Q1 2021.
  • Historically, Enterprise Value has averaged -$19.8 million across 5 years, with a median of -$15.1 million in 2023.
  • The widest YoY moves for Enterprise Value: up 97.29% in 2023, down 989.15% in 2023.
  • Tracing IMDX's Enterprise Value over 5 years: stood at -$1.8 million in 2021, then soared by 52.1% to -$866000.0 in 2022, then plummeted by 989.15% to -$9.4 million in 2023, then increased by 8.44% to -$8.6 million in 2024, then tumbled by 42.57% to -$12.3 million in 2025.
  • Business Quant data shows Enterprise Value for IMDX at -$12.3 million in Q4 2025, -$19.4 million in Q3 2025, and -$24.3 million in Q2 2025.